Systems biology network reveals the correlation between COX-2 expression and Ch 7q copy number alterations in Ch 11q-deleted pediatric neuroblastoma tumors

Copyright: © 2022 Gradowski Farias da Costa do Nascimento et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Tumor-associated inflammation and chromosomal aberrations can play crucial roles in cancer development and progression. In neuroblastoma (NB), the enzyme cyclooxygenase-2 (COX-2) is associated with copy number alterations on the long arm of chromosome 11 (Ch 11q), defining an aggressive disease subset. This retrospective study included formalin-fixed paraffin-embedded tumor samples collected from nine patients during diagnosis at the pediatric Pequeno Principe Hospital, Curitiba, PR, Brazil, and post-chemotherapy (CT). COX-2 expression was evaluated using immunohistochemistry and correlated with the genome profile of paired pre- and post-CT samples, determined by array comparative genomic hybridization. A systems biology approach elucidated the PTGS2 network interaction. The results showed positive correlations between pre-CT Ch 7q gain and COX-2 expression (ρ = 0.825; p-value = 0.006) and negative correlations between Ch 7q gain and Ch 11q deletion (ρ = −0.919; p-value = 0.0005). Three samples showed Ch 11q deletion and Ch 7q gain. Network analysis identified a direct connection between CAV-1 (Ch 7q) and COX-2 in NB tumors and highlighted the connection between amplified genes in Ch 7q and deleted ones in 11q. The identification of hub-bottleneck-switch genes provides new biological insights into this connection between NB, tumorigenesis, and inflammation.

INTRODUCTION

Neuroblastoma (NB) is the most frequent extracranial solid tumor in children, and it accounts for 8–10% of all pediatric cancers [1]. NB tumors originate from neural crest cells, which are primitive progenitors of sympathetic ganglia that can arise anywhere along the sympathetic nervous system [2]. NB presentation differs from other solid tumors because it is highly heterogeneous and ranges from tumors that undergo spontaneous regression to tumors with a highly aggressive profile [1].

MYCN oncogene amplification (MNA) is an independent poor prognostic factor significantly associated with unfavorable histological features [3]. Tumor cell ploidy and segmental chromosomal aberrations, which are frequently found in chromosomes 1p, 1q, 3p, 11q, 14q, and 17p, have substantially improved NB risk stratification [3, 4]. Specifically, loss of heterozygosity (LOH) in chromosome 11q (Ch 11q) in nonamplified-MYCN (NAMN) was found to be associated with a therapy-resistant metastatic NB subgroup [5] as well as with high activity of the cyclooxygenase (COX)/microsomal prostaglandin E synthase (mPGES)-1/PGE2 pathway [6].

Prostaglandins (PGs) are arachidonic acid-derived chemical mediators of inflammatory response [7] produced by sequential actions of COX-1, COX-2, and specific synthases. Aberrant COX-2 expression are often found in tumor cells by [8], cancer-associated fibroblasts and type-2 tumor-associated macrophages [9]. In the tumor microenvironment, COX-2 decreases the apoptosis of tumor cells by upregulating the expression of the anti-apoptotic protein survivin [10], impairing cell adhesion by downregulating E-cadherin [11], and promoting epithelial to mesenchymal transition (EMT) by upregulating miR-526b expression [12]. Other studies have shown that COX-2 expression can be associated with angiogenesis, tumor cell proliferation, and survival and correlates with invasiveness and resistance to chemotherapeutic drugs in many cancer types [13].

Chemotherapy (CT) can induce changes in residual and relapsed tumors [14], either by the survival of minor clones and their expansion during CT or by the development of genetic alterations in tumor cells that promote their survival and resistance to the same treatment. Recently, cytotoxic therapy has been shown to acutely enhance COX-2 transcription and PGE2 production in cancer cells, which modifies the tumoral inflammatory response and the efficacy of cytotoxic- and immuno-therapies, although such responses are only observed in tumors with prior activation of the pathway and basal levels of COX-2 mRNA [15]. This finding reinforces the idea that the inflammatory profile and COX-2 expression in the tumor environment prior to treatment may influence the potential therapeutic response. In the current study, we analyzed the COX-2 levels in NB tumor samples and correlated this expression with segmental chromosome aberrations. Using a pipeline of computational systems biology tools, we investigated the direct and indirect connections between PTGS2 and correlated aberrations to search for new insights on inflammation in the pathophysiology of high-risk NB.

RESULTS

COX-2 expression was positively correlated with Ch 7q amplification in pre-CT primary tumors

COX-2 seemed to be randomly expressed in the tumor samples. The highest levels were found in the post-CT samples Pat13, Pat20, and Pat81. Inversely, higher expression was found in the pre-CT samples Pat15 and 42, relative to the post-CT counterparts.

An a-CGH analysis of the paired sample sets (n = 9) revealed that the median (min-max) of the copy number alterations (CNAs) in each case did not significantly differ between pre-CT [11, 3–47] and post-CT [9, 7–29] (p-value = 0.867) (Figure 1A). The most frequent affected cytobands occurring in at least 30% of cases were compared in the paired samples (Figure 1B). The CNA distribution and frequency varied randomly between pre- and post-CT tumor samples. Cytoband 10q11-q26 (loss) was exclusively found in the pre-CT samples. In contrast, the CNA frequency was higher after CT in Ch 2p (44%), 4p (55%), and 17q (66%).

A correlation analysis was performed that included clinical data, copy number alterations, and COX-2 immunoexpression, with correlations at p ≤ 0.05 considered significant (Supplementary Table 1). As expected, overall survival (OS) was inversely correlated with age at diagnosis (Spearman ρ = −0.828, p-value = 0.042). Positive correlations between COX-2 expression and Ch 7p22.3 gain (ρ = 0.825; p-value = 0.006) and Ch 7q11.23-q36.3 gain (ρ = 0.825; p-value = 0.006) were found in the pre-CT samples. Also, a strong inverse correlation was observed between Ch 7q11.23-q36.3 gain and Ch 11q13.4-q25 deletion (ρ = −0.919; p-value = 0.0005) in pre-CT samples. In the post-CT analysis, a correlation was observed between COX-2 post-CT expression and tumor regression (ρ = 0.760; p-value = 0.0028). Therefore, the three patient samples that had the amplification at Ch 7q, the deletion at Ch 11q, and COX-2 expression (Pat15, Pat20, and Pat42) were selected for analysis using systems biology techniques.

Hub-bottleneck-switches present on Ch 7q and 11q connect these alterations to NB tumors and altered COX-2 expression

Pre-CT samples of Pat15, Pat20, and Pat42 that presented aberrations in Ch 7q11.23-q36.3 and Ch 11q 13.4-q25 (Figure 1) were further investigated using a systems biology approach. Genes located within these cytobands were identified for the construction of a protein-protein interaction (PPI) network. Similarly, protein-coding genes located at Ch 1q21-q44 and Ch 9q34.2-q34.3 were also selected, which resulted in a network with 901 nodes and 2405 edges (Figure 2A). The topological analysis resulted in the identification of 67 hubs, 44 bottlenecks, 71 hub-bottlenecks (HBs), 38 switches, and 107 hub-bottleneck-switches (HBSs) (Supplementary Table 2).HBS analysis showed that 43% of the 107 nodes belonged to Ch 1q, 34% to Ch 7q, 4% to Ch 9q, and 20% to Ch 11q. These nodes can be considered as having higher topological influence, which can be due to their multiple connections and their control of the network information flow. Among the genes present in the deleted region of Ch 11q, we found DNA damage response (DDR)– associated genes such as homolog A, double-strand break repair nuclease (MRE11A), H2A histone family member X (H2AFX), and checkpoint kinase 1 (CHK1). A master regulator of DDR and cell cycle checkpoint kinase, ataxia-telangiectasia mutated (ATM); protein phosphatase 2 scaffold subunit A beta (PPP2R1B), which encodes a subunit of the heterotrimeric protein phosphatase 2 (PP2A). Embryonic ectoderm development (EED) in Ch 11q is part of the polycomb repressive complex 2 (PRC2) together with enhancer of zeste homolog 2 (EZH2), which is also an HBS, but is present in Ch 7q.

In the Ch 7q amplified region, we can highlight the oncogene staphylococcal nuclease and tudor domain containing 1 (SND1) as well as components of the SWI/SNF complex such as actin-like 6B (ACTL6B), a regulator of chromatin, subfamily D, member 3 (SMARCD3) that regulates gene transcription by mobilizing nucleosomes. Also, the proto-oncogene tyrosine–protein kinase Met (MET), together with hepatocyte growth factor (HGF), plays a role in embryogenesis, EMT, growth, and survival of cancer cells and stimulates metastasis. Gene Ontology (GO) analysis for HBS showed “response to hormone stimulus”, “regulation of phosphorylation”, and “signal transduction” as related processes. Once all the nodes present in Ch 11q are deleted in the patients analyzed, their biological functions are compromised. Hence, we highlight that the interactions in network need to be analyzed considering their absence. Thus, the model shown in Figure 3 was built, showing the direct and indirect interactions found between the highlighted HBS.

PPI network reveals a direct connection, not yet explored in NB, between COX-2 and CAV-1

PTGS2 is a bottleneck with direct connections to phospholipase A2 Group IVA (PLA2G4A) in Ch 1q, prostaglandin D2 Synthase (PTGDS) in Ch 9q, and thromboxane synthase 1 (TBXAS1) in Ch 7q, all involved with the COX-2 pathway. Caveolin 1 (CAV-1) in Ch 7q was the only direct connection that was not part of the COX-2 pathway (Figure 2A–2C), and it presented topological relevance in the PPI as a HB.

Clustering analysis led to the identification of 17 clusters, and although the PTGS2 gene was not found in any of them, CAV-1 was found in clusters 5, 6, and 17 (Figure 2D). After performing a GO analysis, cluster 5 was associated with the terms “response to external stimulus”, “regulation of canonical Wnt receptor signaling pathway”, “cell differentiation”, and “cell communication”. In cluster 6, the GO terms included “signaling processes”, and in cluster 17, the terms included “regulation of intracellular protein kinase cascade” (Figure 2D).

Considering these findings, whether the expression of the proteins COX-2 and CAV-1 would be correlated in the formalin-fixed paraffin-embedded (FFPE) pre- and post-CT paired samples was examined. All samples were positive for CAV-1, but a statistically significant association was not found, possibly due to the small sample size.

Although correlations were found between the clinical and genetic variables, no cytobands with coincidental CNAs were identified among the three patient samples analyzed post-CT; thus, building a network was impossible. All three patients presented normal Ch 7q, and Pt20 did not show Ch 11q deletion post-CT (Figure 1B). Due to the direct connection present in the network, CAV-1 was the only node investigated by immunohistochemistry (IHC).

DISCUSSION

In the last few decades, the importance of the inflammatory responses in determining disease progression in patients with cancer has become recognized [16, 17] and treatments targeting inflammatory pathways serve as a therapeutic option for NB and other types of cancer. High-risk NB, in particular, the therapy-resistant subset with chromosome 11q-deletion, was suggested to be inflammatory driven and characterized by high activation of the PGE2 pathway with poor treatment response [6]. In the present study, we showed that expression of COX-2, a key enzyme in the pathway, did not significantly differ between pre- and post-CT samples and did not correlate with 11q-deletion. However, a positive correlation was revealed between COX-2 and Ch 7q gain in the pre-CT samples, which in turn inversely correlates with 11q deletions. Our PPI network presented a direct connection of PTGS2 with CAV-1 and highlighted topologically relevant nodes in both chromosomes, revealing that the regulation of COX-2 in NB tumors may be based on complex interactions among proteins coded in Ch 7q11.23-q36.3 and Ch 11q13.4-q25 (Figure 3).

CAV-1 is a member of a family of structural proteins, and it regulates inflammatory mediator production [18]. Previous studies have shown COX-2 and CAV-1 colocalization at the plasma membrane of cancer-associated fibroblasts [19], as well as the positive correlation of their expression within plasma membrane caveolae-like structures in lobular breast cancer cells [20]. Functionally, the augmented expression in tumor cells with low basal levels of CAV-1 reduced COX-2 mRNA and protein levels, beta-catenin-Tcf/Lef and COX-2 gene reporter activity, PGE2 production, and cell proliferation [21]. Apolipoprotein A1 (APOA1), located in the Ch 11q deleted region, was previously reported as an inhibitor of COX-2 expression in colorectal cancer, which results in the negative regulation of phospholipid-transporting ATPase ABCA1. ABCA1 is significantly overexpressed in patients in advanced stages of colorectal cancer, and its overexpression confers proliferative advantages by regulating CAV-1 stability [22]. APOA1 is an HBS node in the network, connecting COX-2, CAV-1, and Ch 11q in NB tumors.

The polycomb repressive complex 2 (PRC2) is responsible for an epigenetic role in cancer development, progression, and prognosis. It is formed by the association of EZH2 (Ch 7q HBS), with two additional proteins, EED (Ch 11q HBS) and Suppressor of zeste 12 (SUZ12). In our pre-CT data, this complex was not formed once EED was deleted. EED is considered a core component that interacts with EZH2 through a WD40 domain, while EZH2 is the catalytic unit of PRC2 [23]. The absence of EED is related to a loss of PRC2 methylation function in embryonic stem cells [24, 25]. In MYCN-amplified NB, EED knockdown inhibited NB cell proliferation [26], and the amplification of EZH2 acted to prevent cell differentiation [27]. Usually, high-risk NB patients, after consolidation therapy, undergo myeloablative autologous hematopoietic stem cell transplantation, local radiation, and then immunotherapy with differentiation therapy as the maintenance phase [1]. In breast cancer, EZH2 promotes the expression of nuclear factor-κB (NF-κB) targets and tumor cell growth independent of its histone methyltransferase activity [28]. NF-κB is a transcription factor responsible for the induction of pro-survival genes and several chemokines and cytokines; it is also a key regulator in the production of COX-2 [29]. None of our patients presented a deletion in Ch 7q (Figure 1B), suggesting that the EZH2 may be acting without interference. In gall bladder carcinoma (GBC), EZH2 and COX-2 were chosen as biomarkers and considered future targets in GBC therapy [30]. EZH2 also promotes tumor progression in pancreatic [31] and prostate cancers [32]. Moreover, in prostate cancer, it was found that genomic amplification in the region Ch 7q31-36 could result in downregulating CAV1, while overexpressing EZH2. This interaction was not a direct connection in our network.

The somatic alterations found in Ch 7q and Ch 11q are complex, and more than one gene may likely be involved in tumorigenesis and progression. Besides the HBS connecting Ch 7q and Ch 11q, there are some that may alone influence COX-inflammation-NB triangle. The HGF/MET complex has been reported to signal migration and/or differentiation of neural crest cell-derived structures [33], via overexpression, amplification, aberrant splicing, or mutations, associated with many cancer types [34, 35]. The HGF/MET complex can also influence COX-2 expression in glioma cells where complex signaling promotes PGE2 release, up-regulating COX-2 expression [36]. ATM, another gene absent due to Ch 11q deletion, may play a role in NB and inflammation. An ATM/p53/Cox-2/PGE2 pathway described in non-small cell lung cancer (NSCLC) post-radiotherapy demonstrated that the ATM/p53 cascade increased production of COX-2/PGE2 in the presence of activated caspase-3 [37].

Our study had limitations based on the number of samples, which prevented the possibility of an association between COX-2 expression and clinical aspects of the disease. Nonetheless, the systems biology approach provided a direction and indicated that aberrations in Ch 7q may affect the regulation of COX-2 in Ch 11q-deleted NB tumors. This study also highlights the possible relation between the inflammatory process and cancer through DNA damage and epigenetic changes on important candidates, both Ch 7q and Ch 11q, and their interaction with each other. Further studies are needed to understand the exact mechanisms underlying this phenomenon. Validating these findings may confirm the ability of Ch 7q to interfere with COX-2 expression in NB.

MATERIALS AND METHODS

Study design and tumor samples

This is a retrospective study conducted using data and tumor samples from pediatric patients diagnosed with neuroblastoma and treated at the Pequeno Príncipe Pediatric Hospital (HPP), Curitiba, PR, Brazil, between 2004 and 2014. A consecutive series of 76 patients were selected for the study. Of these, nine cases presented paired pre- and post-CT FFPE samples with positive COX-2 immunoexpression and good-quality DNA for analysis a-CGH and were included in the study (Supplementary Figure 1). Ethical approval was obtained from the ethics committee of our institute (approval number 33.573.221), and all patients were kept anonymous. The human samples were analyzed following international and national regulations in accordance with the Declaration of Helsinki.

Clinical data were obtained from the Medical Archives and Statistics Service of HPP, and FFPE blocks were obtained from the HPP Biobank. Each tumor specimen was classified according to the following criteria: (i) age at diagnosis (<18 or ≥18 months); (ii) sex; (iii) Shimada classification [38] (favorable or unfavorable histological features); (iv) INSS-based staging (1–4 or 4S); (v) Children’s oncology group (COG)-risk classification [39]; and (vi) clinical course of disease (alive without disease, relapsed, or deceased). The clinical characteristics of this set of patients along with the percentage of COX-2 in each sample are presented in Table 1. The average age at diagnosis was 26 months, with the ages ranging from 0 to 67 months. All cases had unfavorable Shimada classifications [38] and two cases (22%) presented MNA with >4 MYCN copies. In five cases, the adrenal gland was listed as the primary tumor location, while bone marrow infiltration was listed in three. Classification according to the International NB staging system (INSS) [40] showed stage 4 as the most frequent (67%), while according to the COG-risk classification, five cases (56%) were included as high-risk NB [39]. Seven patients (78%) died of the disease.

Tissue microarray construction and immuno-histochemical analysis

The immunohistochemistry assay was preceded by the preparation of multisample paraffin tissue blocks (tissue microarray, TMA). The representative areas of tumors were previously identified and demarcated. Two 4 µm thick cylindrical fragments 0.3 cm in diameter were extracted from the original (donor) blocks and were compiled into new TMA blocks. Sections were analyzed by IHC as previously described [41], with modifications. Antigen retrieval was performed using the BioSB^®™ immunoretriever (Santa Bárbara, USA). The TMAs were incubated overnight with a primary rabbit polyclonal anti-COX-2 (1:200; Spring Bioscience, USA), or primary rabbit monoclonal anti-Caveolin-1 (1:200; BioSB, USA). Secondary–horseradish peroxidase (HRP)–conjugated antibody (Reveal Polyvalent HRP-DAB Detection System, Spring Bioscience, USA) was incubated for 30 min at room temperature. Positive (colon cancer specimens) and negative (omitting primary antibodies) controls were run in parallel in each of the reactions. The images were obtained using a Zeiss Axioscan Slide Scanner (Jena, Germany) in high power fields (20× magnification), with a total area of 90,472.78 µm². IHC expression was evaluated through quantitative analyses of cytoplasmic staining images using Image-Pro Plus^® software (Rockville, MD, USA) and calculated as a percentage of the ratio of positive staining area per the total area [42].

MYCN amplification status

The MYCN oncogene amplification status was assayed by fluorescence in situ hybridization on the TMA slides using a direct commercial probe (Surefish 2p24 MYCN 277kb p5; Agilent Technologies Inc., Santa Clara, CA, USA). Briefly, the TMA sections were deparaffinized and treated with HCl (0.2N), followed by proteolytic digestion with pepsin (750 U/ml). Hybridization was performed overnight at 37°C in a humidified chamber. The slides were counterstained with 0.2 μmol DAPI in an antifade solution. Samples were analyzed in a blinded manner by manual counting by two independent investigators (S.E.E. and L.R.C.). Digital images were obtained using a confocal microscope (NIKON Instruments Inc., Tokyo, Japan). MYCN was considered amplified in samples with ≥4 positive signals.

Array–comparative genomic hybridization analysis

DNA copy number analysis was performed using an oligonucleotide a-CGH platform (SurePrint G3 Human CGH Microarray 8x60K; Agilent Technologies Inc., Santa Clara, CA, USA), using a previously established protocol for FFPE samples [43, 44]. DNA was isolated using the standard phenol-chloroform method. Reference DNA was prepared from the peripheral blood of a pool of ten healthy donors [45]. Equal amounts of tumor and reference genomic DNA (1–2 µg) were digested, enzymatically labeled using the SureTag Complete DNA Labeling Kit (Agilent Technologies, Inc., Santa Clara, CA, USA), and hybridized to the arrays. The array data were analyzed with the Feature Extraction v.10.10 software and Agilent CytoGenomics v.3.0 software (Agilent Technologies Inc., Santa Clara, CA, USA) using the ADM-2 algorithm, threshold 6.0, and an aberration filter with a minimum of >3 probes [45]. Copy number gains and losses were defined as previously described [44].

Systems biology analysis

The protein-coding genes from Ch 1q21.3-q42.2, 7q11.23-q36.3, 9q34.2-34.3, and 11q13.4-q25 were used as inputs to generate a Homo sapiens PPI network using the STRING database v.11.0 [46]. All active interaction sources included experiments, databases, co-expression, neighborhood, gene fusion, and co-occurrence, but not text mining. The minimum required interaction score was set at medium confidence (0.400). The PPI data were transferred to the Cytoscape v.3.9 software [47], and the CentiScape 2.2 plug-in [48] was used to select the centralities in the whole network. The degree, betweenness, and eigenvector centralities were calculated for the topological analyses. Degree measures how many direct neighbors are connected to a given node, and nodes with above-average degree values are hubs. A bottleneck is a node with above average betweenness, which significantly influences the network structure. HBs represent a node with above-average degree and betweenness. Finally, the eigenvector centrality assigns a relative score to all the nodes in the network based on the concept that connections to high-scoring nodes highly contribute to the network. High eigenvector denotes switches in the network. Nodes with above-average scores in all three centralities are classified as HBSs and have a key influence in regulating molecular networks [49]. Cluster formation was investigated with the Molecular Complex Detection (MCODE) app [50]. Loops, Haircut, and Fluff were chosen in the network using the advanced options. The cut-off point was delimited as nodes >10 and number of connections >3. The Biological Networks Gene Ontology (BiNGO) plug-in was used to investigate Gene Ontologies 34, with hypergeometric testing and the Bonferroni family-wise correction with a significance level of p ≥ 0.05. All non-specific bioprocesses, such as regulation of the biological process and regulation of the metabolic process, were excluded for further analysis considering their lack of biological meaning.

Statistical analysis

Patient sex, age-related risk, tumor stage, Shimada status, recurrence, death, and clinical follow-up data were distributed in relative frequencies. A correlation analysis of COX-2 expression pre-and post-CT was performed by Student’s t-test (paired and unpaired), and CNAs pre- and post-CT were compared by the Wilcoxon signed-rank test. The correlation analysis among clinical data, COX-2 and CAV-1 immunoexpression, and CNAs was performed with a parametric correlation Pearson’s test and nonparametric correlation Spearman’s and Kendall’s Tau-b tests, with a two-tailed analysis. For these analyses, CNAs were categorized as unaltered (0), loss or deletion (−1), and gain or amplification (+1). All statistical analyses were performed using IBM SPSS Statistics (IBM Corp., Version 23.0, Armonk, NY) and GraphPad Prism (version 9.0.0, GraphPad Software, San Diego, CA, USA) software, with p < 0.05 considered significant.

Abbreviations

a-CGH: Array–comparative genomic hybridization; APOA1: Apolipoprotein A1; ABCA1: Phospholipid-transporting ATPase ABCA1; ACTL6B: Actin Like 6B; ATM: Ataxia Telangiectasia Mutated; BiNGO: Biological networks gene ontology; CAV: Caveolin; CHK1: Checkpoint Kinase 1; CNAs: Copy number alterations; COG: Children’s oncology group; COX: Cyclooxygenases; CT: Chemotherapy; DDR: DNA damage response; EED: Embryonic Ectoderm Development; EMT: Epithelial to mesenchymal transition; EZH2: Enhancer of zeste Homolog 2; FFPE: Formalin-fixed paraffin-embedded; FISH: Fluorescence in situ hybridization; GBC: Gall bladder carcinoma; GN: Ganglioneuroma; H2AFX: H2A Histone Family Member X; HB: Hub-bottlenecks; HBS: Hub-bottleneck-switches; HGF: Hepatocyte Growth Factor; HPP: Hospital Pequeno Príncipe; IHC: Immunohistochemistry; INSS: International NB staging system; LOH: Loss of heterozygosity; MCODE: Molecular complex detection; MET: Tyrosine-Protein Kinase Met; MNA: MYCN oncogene amplification; mPGES: Microsomal prostaglandin E synthase; MRE11A: Double-Strand Break Repair Nuclease; NAMN: Nonamplified-MYCN; NB: Neuroblastoma; NF-κB: Nuclear factor-κB; NSCLC: Non-small cell lung cancer; OS: Overall survival; PG: Prostaglandins; PLA2G4A: Phospholipase A2 Group IVA; PP2A: Heterotrimeric protein phosphatase 2; PPI: Protein-protein interaction; PPP2R1B: Protein Phosphatase 2 Scaffold Subunit A beta; PRC2: Polycomb repressive complex 2; PTGDS: Prostaglandin D2 Synthase; PTGS2: Prostaglandin-endoperoxide synthase 2; SMARCD3: Regulator of Chromatin, Subfamily D, Member 3; SND1: Staphylococcal Nuclease and Tudor Domain Containing 1; SUZ12: Suppressor of zeste 12; TBXAS1: Thromboxane synthase 1; TMA: Tissue microarray.

Author contributions

TGFN performed systems biology analysis and contributed to the manuscript preparation. MET performed systems biology analysis and statistical analysis. NFJ and LCP performed the IHC assay and patient clinical data collection. ASF assisted in the a-CGH assays. SHW supervised the statistical analysis. RHH and BCF coordinated the bioinformatics and systems biology analyses, contributed to scientific discussions, and revised the final version for intellectual contribution. BF coordinated patient data collection. LN contributed to the design of the study and performed pathological analyses. LRC coordinated a-CGH and fluorescence in situ hybridization (FISH) analysis and contributed to the final revision of the manuscript. SEE designed the study, performed a-CGH and FISH assays, and wrote the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors thank the GESR of the Lombardi Comprehensive Cancer Center (Washington DC, USA) for washing and scanning the a-CGH slides, and the Center for Advanced Technologies in Fluorescence (CTAF) at the Federal University of Paraná (Curitiba, PR, Brazil) for performing FISH confocal microscopy imaging. We also acknowledge CAPES for Dr. Bruno C. Feltes postdoctoral fellowship and Ms. Akanksha Mahajan (MSc) for the technical support with a-CGH and FISH analyses.

CONFLICTS OF INTEREST

Authors have no conflicts of interest to declare.

Ethical statement and consent

The present study was approved by the Human Research Ethics Committee of the Pontifícia Universidade Católica do Paraná (Curitiba, PR, Brazil) under the registration number 3.573.221/2019. The analysis of the human samples used in the present study was performed following the international and national regulations in accordance with the Declaration of Helsinki.

FUNDING

Scholarships to Dr. Lisiane C Poncio, Ms. Thatyanne GF do Nascimento, and Mr. Nilton de F Junior were provided by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil; Finance code 001), and the scholarship to Dr Aline S Fonseca was provided by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil). Additionally, the Genomics and Epigenomics Shared Resource (GESR) partially supported the present study (grant no. P30-CA051008).

• 1. Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018; 372:195–209. https://doi.org/10.1007/s00441-018-2821-2. [Pubmed]
• 2. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers. 2016; 2:16078. https://doi.org/10.1038/nrdp.2016.78. [Pubmed]
• 3. Aygun N. Biological and Genetic Features of Neuroblastoma and Their Clinical Importance. Curr Pediatr Rev. 2018; 14:73–90. https://doi.org/10.2174/1573396314666180129101627. [Pubmed]
• 4. Costa RA, Seuánez HN. Investigation of major genetic alterations in neuroblastoma. Mol Biol Rep. 2018; 45:287–95. https://doi.org/10.1007/s11033-018-4161-4. [Pubmed]
• 5. Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F. 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer. 2017; 16:114. https://doi.org/10.1186/s12943-017-0686-8. [Pubmed]
• 6. Larsson K, Kock A, Idborg H, Arsenian Henriksson M, Martinsson T, Johnsen JI, Korotkova M, Kogner P, Jakobsson PJ. COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc Natl Acad Sci U S A. 2015; 112:8070–75. https://doi.org/10.1073/pnas.1424355112. [Pubmed]
• 7. Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: A review. J Cell Physiol. 2019; 234:5683–99. https://doi.org/10.1002/jcp.27411. [Pubmed]
• 8. Harizi H. Epigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequences. Mediators Inflamm. 2015; 2015:841097. https://doi.org/10.1155/2015/841097. [Pubmed]
• 9. Pannunzio A, Coluccia M. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature. Pharmaceuticals (Basel). 2018; 11:101. https://doi.org/10.3390/ph11040101. [Pubmed]
• 10. Yang Y, Zhu J, Gou H, Cao D, Jiang M, Hou M. Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol. 2011; 28:796–803. https://doi.org/10.1007/s12032-010-9519-y. [Pubmed]
• 11. Watanabe Y, Imanishi Y, Ozawa H, Sakamoto K, Fujii R, Shigetomi S, Habu N, Otsuka K, Sato Y, Sekimizu M, Ito F, Ikari Y, Saito S, et al. Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer. Am J Transl Res. 2020; 12:1096–113. [Pubmed]
• 12. Majumder M, Landman E, Liu L, Hess D, Lala PK. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation. Mol Cancer Res. 2015; 13:1022–33. https://doi.org/10.1158/1541-7786.MCR-14-0543. [Pubmed]
• 13. Tong D, Liu Q, Wang LA, Xie Q, Pang J, Huang Y, Wang L, Liu G, Zhang D, Lan W, Jiang J. The roles of the COX2/PGE2/EP axis in therapeutic resistance. Cancer Metastasis Rev. 2018; 37:355–68. https://doi.org/10.1007/s10555-018-9752-y. [Pubmed]
• 14. Ibragimova MK, Tsyganov MM, Litviakov NV. Natural and Chemotherapy-Induced Clonal Evolution of Tumors. Biochemistry (Mosc). 2017; 82:413–25. https://doi.org/10.1134/S0006297917040022. [Pubmed]
• 15. Bell CR, Pelly VS, Moeini A, Chiang SC, Flanagan E, Bromley CP, Clark C, Earnshaw CH, Koufaki MA, Bonavita E, Zelenay S. Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nat Commun. 2022; 13:2063. https://doi.org/10.1038/s41467-022-29606-9. [Pubmed]
• 16. Piotrowski I, Kulcenty K, Suchorska W. Interplay between inflammation and cancer. Rep Pract Oncol Radiother. 2020; 25:422–27. https://doi.org/10.1016/j.rpor.2020.04.004. [Pubmed]
• 17. Murata M. Inflammation and cancer. Environ Health Prev Med. 2018; 23:50. https://doi.org/10.1186/s12199-018-0740-1. [Pubmed]
• 18. Capozza F, Trimmer C, Castello-Cros R, Katiyar S, Whitaker-Menezes D, Follenzi A, Crosariol M, Llaverias G, Sotgia F, Pestell RG, Lisanti MP. Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice: role of Cav1 in Shh heterotypic signaling and transendothelial migration. Cancer Res. 2012; 72:2262–74. https://doi.org/10.1158/0008-5472.CAN-11-2593. [Pubmed]
• 19. Shen XJ, Zhang H, Tang GS, Wang XD, Zheng R, Wang Y, Zhu Y, Xue XC, Bi JW. Caveolin-1 is a modulator of fibroblast activation and a potential biomarker for gastric cancer. Int J Biol Sci. 2015; 11:370–79. https://doi.org/10.7150/ijbs.10666. [Pubmed]
• 20. Perrone G, Zagami M, Altomare V, Battista C, Morini S, Rabitti C. COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast. Virchows Arch. 2007; 451:1039–45. https://doi.org/10.1007/s00428-007-0506-4. [Pubmed]
• 21. Rodriguez DA, Tapia JC, Fernandez JG, Torres VA, Muñoz N, Galleguillos D, Leyton L, Quest AF. Caveolin-1-mediated suppression of cyclooxygenase-2 via a betacatenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell. 2009; 20:2297–310. https://doi.org/10.1091/mbc.e08-09-0939. [Pubmed]
• 22. Aguirre-Portolés C, Feliu J, Reglero G, Ramírez de Molina A. ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. Mol Oncol. 2018; 12:1735–52. https://doi.org/10.1002/1878-0261.12367. [Pubmed]
• 23. Yu W, Zhang F, Wang S, Fu Y, Chen J, Liang X, Le H, Pu WT, Zhang B. Depletion of polycomb repressive complex 2 core component EED impairs fetal hematopoiesis. Cell Death Dis. 2017; 8:e2744. https://doi.org/10.1038/cddis.2017.163. [Pubmed]
• 24. von Schimmelmann M, Feinberg PA, Sullivan JM, Ku SM, Badimon A, Duff MK, Wang Z, Lachmann A, Dewell S, Ma’ayan A, Han MH, Tarakhovsky A, Schaefer A. Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration. Nat Neurosci. 2016; 19:1321–30. https://doi.org/10.1038/nn.4360. [Pubmed]
• 25. Lee CH, Holder M, Grau D, Saldaña-Meyer R, Yu JR, Ganai RA, Zhang J, Wang M, LeRoy G, Dobenecker MW, Reinberg D, Armache KJ. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2. Mol Cell. 2018; 70:435–48.e5. https://doi.org/10.1016/j.molcel.2018.03.019. [Pubmed]
• 26. Shaliman D, Takenobu H, Sugino RP, Ohira M, Kamijo T. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma. Eur J Cell Biol. 2022; 101:151238. https://doi.org/10.1016/j.ejcb.2022.151238. [Pubmed]
• 27. Wang L, Chen C, Song Z, Wang H, Ye M, Wang D, Kang W, Liu H, Qing G. EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. Nat Commun. 2022; 13:12. https://doi.org/10.1038/s41467-021-27609-6. [Pubmed]
• 28. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, Liou YC, Yu Q. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell. 2011; 43:798–810. https://doi.org/10.1016/j.molcel.2011.08.011. [Pubmed]
• 29. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011; 12:715–23. https://doi.org/10.1038/ni.2060. [Pubmed]
• 30. Gupta A, Gupta S, Mani R, Durgapal P, Goyal B, Rajput D, Rao S, Dhar P, Gupta M, Kishore S, Kant R. Expression of Human epidermal growth factor receptor 2, Survivin, Enhancer of zeste homolog -2, Cyclooxygenase-2, p53 and p16 molecular markers in Gall bladder carcinoma. J Carcinog. 2021; 20:7. https://doi.org/10.4103/jcar.JCar_4_21. [Pubmed]
• 31. Patil S, Steuber B, Kopp W, Kari V, Urbach L, Wang X, Küffer S, Bohnenberger H, Spyropoulou D, Zhang Z, Versemann L, Bösherz MS, Brunner M, et al. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Res. 2020; 80:4620–32. https://doi.org/10.1158/0008-5472.CAN-20-0672. [Pubmed]
• 32. Bachmann N, Haeusler J, Luedeke M, Kuefer R, Perner S, Assum G, Paiss T, Hoegel J, Vogel W, Maier C. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet Cytogenet. 2008; 182:103–10. https://doi.org/10.1016/j.cancergencyto.2008.01.006. [Pubmed]
• 33. Rozen EJ, Shohet JM. Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology. Cancer Metastasis Rev. 2022; 41:33–52. https://doi.org/10.1007/s10555-021-10001-7. [Pubmed]
• 34. Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013; 19:6163–72. https://doi.org/10.1158/1078-0432.CCR-12-3826. [Pubmed]
• 35. Lee J, Ou SH, Lee JM, Kim HC, Hong M, Kim SY, Jang J, Ahn S, Kang SY, Lee S, Kim ST, Kim B, Choi J, et al. Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget. 2015; 6:28211–22. https://doi.org/10.18632/oncotarget.4721. [Pubmed]
• 36. Zhao Y, Sun Y, Zhang H, Liu X, Du W, Li Y, Zhang J, Chen L, Jiang C. HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production. Int J Clin Exp Pathol. 2015; 8:3719–26. [Pubmed]
• 37. Zhao M, Wang Y, Zhao Y, He S, Zhao R, Song Y, Cheng J, Gong Y, Xie J, Wang Y, Hu B, Tian L, Huang Q. Caspase-3 knockout attenuates radiation-induced tumor repopulation via impairing the ATM/p53/Cox-2/PGE2 pathway in non-small cell lung cancer. Aging (Albany NY). 2020; 12:21758–76. https://doi.org/10.18632/aging.103984. [Pubmed]
• 38. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999; 86:349–63. [Pubmed]
• 39. Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015; 62:225–56. https://doi.org/10.1016/j.pcl.2014.09.015. [Pubmed]
• 40. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11:1466–77. https://doi.org/10.1200/JCO.1993.11.8.1466. [Pubmed]
• 41. Vaz de Paula CB, Nagashima S, Liberalesso V, Collete M, da Silva FPG, Oricil AGG, Barbosa GS, da Silva GVC, Wiedmer DB, da Silva Dezidério F, Noronha L. COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis. Int J Mol Sci. 2021; 23:168. https://doi.org/10.3390/ijms23010168. [Pubmed]
• 42. Vaz de Paula CB, de Azevedo MLV, Nagashima S, Martins APC, Malaquias MAS, Miggiolaro AFR, da Silva Motta Júnior J, Avelino G, do Carmo LAP, Carstens LB, de Noronha L. IL-4/IL-13 remodeling pathway of COVID-19 lung injury. Sci Rep. 2020; 10:18689. https://doi.org/10.1038/s41598-020-75659-5. [Pubmed]
• 43. Santos SC, Cavalli IJ, Ribeiro EM, Urban CA, Lima RS, Bleggi-Torres LF, Rone JD, Haddad BR, Cavalli LR. Patterns of DNA copy number changes in sentinel lymph node breast cancer metastases. Cytogenet Genome Res. 2008; 122:16–21. https://doi.org/10.1159/000151311. [Pubmed]
• 44. Torresan C, Oliveira MM, Pereira SR, Ribeiro EM, Marian C, Gusev Y, Lima RS, Urban CA, Berg PE, Haddad BR, Cavalli IJ, Cavalli LR. Increased copy number of the DLX4 homeobox gene in breast axillary lymph node metastasis. Cancer Genet. 2014; 207:177–87. https://doi.org/10.1016/j.cancergen.2014.04.007. [Pubmed]
• 45. Sugita B, Gill M, Mahajan A, Duttargi A, Kirolikar S, Almeida R, Regis K, Oluwasanmi OL, Marchi F, Marian C, Makambi K, Kallakury B, Sheahan L, et al. Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women. Oncotarget. 2016; 7:79274–91. https://doi.org/10.18632/oncotarget.13024. [Pubmed]
• 46. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. STRING v11: proteinprotein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47:D607–13. https://doi.org/10.1093/nar/gky1131. [Pubmed]
• 47. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13:2498–504. https://doi.org/10.1101/gr.1239303. [Pubmed]
• 48. Scardoni G, Tosadori G, Faizan M, Spoto F, Fabbri F, Laudanna C. Biological network analysis with CentiScaPe: centralities and experimental dataset integration. F1000Res. 2014; 3:139. https://doi.org/10.12688/f1000research.4477.2. [Pubmed]
• 49. Feltes BC, Poloni JF, Nunes IJG, Faria SS, Dorn M. Multi-Approach Bioinformatics Analysis of Curated Omics Data Provides a Gene Expression Panorama for Multiple Cancer Types. Front Genet. 2020; 11:586602. https://doi.org/10.3389/fgene.2020.586602. [Pubmed]
• 50. Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003; 4:2. https://doi.org/10.1186/1471-2105-4-2. [Pubmed]

PII: 225